Dr Neal Shore (Carolina Urologic Research Center, South Carolina, USA), Dr Joaquin Mateo (Vall d'Hebron Institute of Oncology, Barcelona, Spain) and Dr Karim Fizazi (Institut Gustave Roussy, Paris, France) discuss the treatment and management of metastatic castration resistant prostate cancer (mCRPC).
Dr Shore provides and overview of the current treatment landscape for mCRPC before Dr Mateo summarises the TOPARP-A study and results of the TOPARP-B study presented at ASCO 2019. The panel then go on to discuss ongoing trials including PROFOUND and TRITON3 as well as summarising the ARAMIS and VISION studies.
The session concludes with Dr Mateo offering advice on how to manage patients on PARP inhibitors and the associated adverse event profile of this class of drugs.
|Current clinical landscape of mCRPC|
|Summary of the TOPARP-A study and the latest results from the TOPARP-B study|
|Role of PARP inhibitors in mCRPC from the PROFOUND and TRITON3 trials|
|Key findings of the ARAMIS trial|
|Prostate-specific membrane antigen (PSMA) as a therapeutic target|
|Overview of the VISION trial|
|Use of bi-specific T-cell engagers (BiTEs) as a treatment option|
|Adverse events associated with PARP inhibitors|
|Genetic testing to identify germline and somatic mutations|
This programme has been supported by an unrestricted educational grant from AstraZeneca.